Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aura Biosciences Inc (NQ: AURA ) 8.740 +0.160 (+1.86%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 92,954 Open 8.600 Bid (Size) 8.740 (1) Ask (Size) 8.750 (1) Prev. Close 8.580 Today's Range 8.510 - 8.850 52wk Range 5.990 - 12.35 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Aura Biosciences Touts Promising Data From Eye Cancer Candidate September 12, 2024 Aura Biosciences announced promising Phase 2 results for bel-sar in treating melanoma, achieving 80% tumor control. Via Benzinga AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024 August 08, 2024 AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Performance YTD -3.21% -3.21% 1 Month +18.27% +18.27% 3 Month +22.24% +22.24% 6 Month +18.11% +18.11% 1 Year +5.30% +5.30% More News Read More AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024 May 09, 2024 Via InvestorPlace AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 March 27, 2024 Via InvestorPlace Recap: Aura Biosciences Q4 Earnings March 27, 2024 Via Benzinga Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights March 27, 2024 From Aura Biosciences, Inc. Via Business Wire Aura Biosciences to Participate in Upcoming Investor Conferences February 26, 2024 From Aura Biosciences Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session January 09, 2024 Via Benzinga Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma December 07, 2023 From Aura Biosciences Inc. Via Business Wire Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying November 10, 2023 Via Benzinga Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights November 09, 2023 From Aura Biosciences, Inc. Via Business Wire Aura Biosciences to Participate in Upcoming Investor Conferences November 08, 2023 From Aura Biosciences Inc. Via Business Wire Why Aura Biosciences Stock Hit A New 52-Week Low Today November 07, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session November 07, 2023 Via Benzinga Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session November 07, 2023 Via Benzinga Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket November 07, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session November 07, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday November 07, 2023 Via InvestorPlace Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session November 07, 2023 Via Benzinga Aura Biosciences Announces Pricing of Public Offering of Common Stock November 06, 2023 From Aura Biosciences, Inc. Via Business Wire 12 Health Care Stocks Moving In Monday's After-Market Session November 06, 2023 Via Benzinga Aura Biosciences Announces Proposed Public Offering of Common Stock November 06, 2023 From Aura Biosciences, Inc. Via Business Wire Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma November 06, 2023 From Aura Biosciences, Inc. Via Business Wire Top 5 Health Care Stocks That May Fall Off A Cliff This Month November 06, 2023 Via Benzinga Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023 October 31, 2023 From Aura Biosciences Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
